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Levels of circulating insulin cell-free DNA in
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longitudinal cohort study
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Marie Louise Muff Wissing1, Anne-Lis Mikkelsen Englund1 and Louise Torp Dalgaard2
Abstract
Background: Women with Polycystic Ovary Syndrome (PCOS) present a heterogeneous reproductive and
metabolic profile with an increased lifetime risk of Type 2 Diabetes (T2D). Early biomarkers of these metabolic
disturbances in PCOS women have not been identified. The abundance of circulating insulin gene promotor cell-
free DNA (INS cfDNA) was shown to be valuable as a predictive biomarker of β-cell death in individuals with Type 1
diabetes (T1D) as well as with gestational diabetes. Since β-cell death is common to the development of T1D as
well as in T2D, we aimed to investigate if insulin-coding DNA is more abundant in circulation of PCOS women (vs
Controls) and if their levels change after 6 yr. follow-up as a potential measure to predict future T2D.
Methods: A cohort of 40 women diagnosed with PCOS according to Rotterdam 2003 criteria and eight healthy
controls were examined at baseline and 6 years follow-up. Clinical measurements for evaluation of glucose
homeostasis as well as blood/serum samples were obtained at each visit. Methylated and unmethylated INS cfDNA
were quantified using droplet digital PCR. Differences between groups were assessed using Kruskall-Wallis test and
Wilcoxon Signed rank test.
Results: At baseline, there was no detectable difference in copy number (copies/μL) of methylated (p = 0.74) or
unmethylated INS cfDNA (p = 0.34) between PCOS and Control groups. At follow up, neither methylated (p = 0.50)
nor unmethylated INScfDNA levels (p = 0.48) differed significantly between these groups. Likewise, when pooling
the groups, there was no difference between baseline and follow up, in terms of copies of methylated or
unmethylated INS cfDNA (p = 0.38 and p = 0.52, respectively). There were no significant correlations between
counts of unmethylated or methylated cfDNA and the clinical measurements of β-cell function and pre-diabetes.
Conclusion: The circulating level of unmethylated and methylated INScfDNA is similar between PCOS and Controls
and cannot be used to predict islet β-cell loss and progression to Type 2 diabetes in a 6-year follow-up.
Trial registration: The Danish Data Protection Agency (REG-31-2016. Approval: 01-12-2015) and by the Danish
Scientific Ethical committee of Region Zealand (Journal no. SJ-525. Approval: 13-06-2016), Clinicaltrials.gov,
(NCT03142633, registered 1. March, 2017, Retrospectively registered).
Keywords: Circulating free DNA, Insulin promoter CpG methylation, Demethylation, PCOS, Glucose tolerance,
Androgens, Testosterone
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Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder of reproductive age women [1]. It is
characterized by hyperandrogenism, polycystic ovary
morphology, and anovulation, but also by metabolic dis-
turbances; increased risk of hypertension, dyslipidemia,
insulin resistance, impaired glucose tolerance (IGT) and
an increased lifetime risk of Type 2 diabetes mellitus
(T2D) [1, 2]. Preventive advice and monitoring for these
future complications are important. However, it is con-
troversial how to monitor women with PCOS according
to the risk of T2D and the guidelines present with some
inconsistencies. The latest recommendation is that mea-
surements of HbA1C, fasting glucose or oral glucose tol-
erance test (OGTT) should be repeated with 1 to 3 years
interval, according to additional risk factors and an
OGTT should be offered when planning pregnancy or
seeking fertility treatment [1]. There is a general consen-
sus that the risk of diabetes increases, corresponding to
age and increasing BMI [2, 3], but to date, no definitive
marker of these metabolic disturbances and T2D has
been identified in women with PCOS. Further, the het-
erogeneous nature of PCOS with differences in meta-
bolic risk profile [4, 5] clarifies the need for new
biomarkers.
The abundance of insulin cfDNA that is unmethylated
at the − 69 position of the Insulin gene has been sug-
gested as a biomarker of β-cell death, as this site is
unmethylated in insulin-producing islet β-cells but
methylated in non-islet cells [6–8]. Methylation of a cer-
tain genomic region is generally regarded as a deactiva-
tion mechanism, and is conducted by DNA
methyltransferases (DMT) that catalyze the addition of a
methyl group from S-adenosyl-methionine to the carbon
in 5′ of cytosine residues in cytosine-phosphate-guanine
(CpG) dinucleotides [9]. The active, unmethylated form
of the insulin gene from β-cells is presumed to be re-
leased into the circulation from dying/dead islet β-cells
[10]. Therefore, the amount of circulating unmethylated
cfDNA would be a reflection of β-cell death, while meth-
ylated cfDNA is suggested to be a marker of cellular
stress and death of cells/tissues that do not transcribe
insulin [11]. An intense search for methods to quantify
methylated and unmethylated insulin cfDNA is ongoing,
as it would enable us to diagnose Type 1 Diabetes (T1D)
and β-cell destruction before the loss of a significant
number of insulin-producing cells. A crucial step in this
process has been to identify CpG-sites within the insulin
gene that are unique to islet β-cells. There are different
approaches to this issue and no consensus of which sites
and methods to apply [10, 12, 13].
Though insulin resistance, hyperglycemia and im-
paired glucose tolerance play a central role in T2D, these
alone are not sufficient to lead to T2D without a β-cell
defect [14]. In patients with early stages of T2D, β-cells
secrete excessive insulin and expand their mass to com-
pensate for the increased metabolic load and
obesity-associated insulin resistance. After a period, the
β-cell function then deteriorates along with loss of β-cell
mass and apoptosis [15, 16]. It is suggested that epigen-
etic modulations could contribute to these alterations in
β-cell function [17]. Currently, only a few groups have
demonstrated the methylation pattern of the insulin
gene in patients with T2D, and most of them only within
the pancreatic tissue of donors, mouse models or pan-
creatic cell lines [6, 7, 18, 19]. Although one study dem-
onstrated that at-risk subjects who progressed to T1D
had higher levels of unmethylated insulin-coding
cell-free DNA (INScfDNA) compared with healthy con-
trols [20], there is no knowledge of whether an increased
amount of unmethylated circulating INScfDNA could
serve as a predictor of T2D, as there are no longitudinal
studies of cohorts with an increased risk of T2D.
Women with PCOS are known to have a higher risk of
IGT and IFG progressing to T2D [2]. Some studies indi-
cate that the IGT is accompanied by a β-cell dysfunction
in PCOS women especially in those with a family history
of T2D [21] and might even occur prior to changes in
stimulated insulin or glucose levels [20]. Since islet
β-cell death is a common denominator to T1D as well
as T2D, we aimed to assess if islet β-cell death, mea-
sured as circulating unmethylated INScfDNA could
serve as a biomarker for risk stratification in PCOS
women who progress to prediabetes or T2D.
Droplet digital (dd) PCR was used to measure the copy
number of INScfDNA in women with PCOS compared
with controls at baseline and at 6 years of follow-up
using the method described by Fisher et al. [13]. We also
investigated whether the abundance of circulating
INScfDNA correlated with markers of insulin resistance
and T2D in women with PCOS.
Methods
Study cohort
This study was a longitudinal cohort study consisting of
40 women between age 23 and 38, diagnosed with PCOS
according to the Rotterdam 2003 criteria [22] and 8
healthy age-match controls, who were recruited at the
Fertility Clinic at Holbæk Hospital, Denmark, as a part
of the PICOLO cohort [23]. They were examined prior
to fertility treatment (Baseline (BL)). The participants
were invited for a physical re-examination 6 years later,
where an OGTT, transvaginal ultrasound, and blood
sampling were performed (Follow-up (FU)). Inclusion
criteria: Former participants of the PICOLO study. Ex-
clusion criteria: Oral Contraceptives (OCP) within 8
weeks from examination, endocrinological disease (i.e.
type 1 and type 2 diabetes, thyroid dysfunction), severe
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endometriosis, premature ovarian insufficiency, breast-
feeding women and pregnancy.
The study was designed and performed according to
the Declaration of Helsinki II and approved by the Da-
nish Data Protection Agency (REG-31-2016) and by the
Danish Scientific Ethical committee of region Zealand
(Journal no. SJ-525). All subjects gave written consent
prior to inclusion.
Anthropometric measurements
Anthropometric and biochemical measurements ob-
tained in this study population have been described pre-
viously [23]. Clinical hyperandrogenism was evaluated
with Ferriman Gallway score. Blood Pressure was con-
sidered elevated If > 140/90 mmHg [24]. Being over-
weight was assessed by BMI > 25 kg/m2 and abdominal
fat by waist-hip circumference (Considered Elevated if
waist-hip circumference > 0.85).
Oral glucose tolerance test (OGTT)
The OGTT was performed after an overnight fast (at
least 8 h). We collected venous blood samples and
measured glucose, plasma insulin and C-peptide at −
5, 0, 30 and 120 min after a 75 g glucose load. Im-
paired fasting glucose (IFG) was defined as fasting
plasma glucose (FPG) > 5.6 mmol/L and < 6.9 mmol/L
and IGT as 2-h plasma glucose between 7.8 mmol/L
and 11.0 mmol/L [24].
Blood sample preparation
Venous blood for digital droplet PCR (ddPCR) was col-
lected in an EDTA tube and kept on ice until centrifuga-
tion. Plasma and cellular fractions were separated by
centrifugation at 1800Xg for 20 min. Plasma was care-
fully removed leaving 0.5 mL in order to avoid disturb-
ance of the interface. The EDTA plasma was stored at
-80 °C until analysis.
DNA extraction from plasma
DNA extraction was performed with QIAmp DNA Blood
Mini Kit (Qiagen) with 10 μg poly-A DNA as a carrier. All
samples were thawed on ice and buffers were prepared ac-
cording to the manufacturer’s recommendations. We used
50 μL EDTA plasma from a first time thaw aliquot for
DNA extraction. All samples then underwent bisulfite
conversion to convert unmethylated cytosine into uracil
using EZ DNA Methylation-Lightning Kit (Zymo Re-
search). Cell-free DNA concentrations were measured
with Qubit™ 4 Fluorometer (Thermofisher Scientific).
Methylated and unmethylated INScfDNA quantifica-
tion using digital droplet PCR (ddPCR):
A MasterMix was prepared using custom SNP Taq-
Man primer/probes [6], that detected methylation or
unmethylation at the CpG site located 69 bp upstream
of the transcription start site (TSS). Primer/probe se-
quences are listed in Additional file 1. Droplets were
generated using an automated droplet generator and
copies of INScfDNA quantitated using a dual fluorescent
probe-based multiplex assay. The selected probe [13]
distinguishes DNA that is differentially methylated at nt
− 69 of the human insulin gene. Plasmids for INScfDNA
(unmethylated, methylated or combinations of these)
were used on each assay plate as positive controls. Inter-
and intra-assay CVs were less than 5% and were satisfac-
tory. The total INScfDNA (copies/μl) represents the sum
of the copies of unmethylated as well as methylated
INScfDNA from each plasma sample.
We added 22.5 μL MasterMix, followed by 2.5 μL of
bisulfite converted (bc) DNA into each well of a 96-well
Eppendorf plate. The PCR reaction-oil droplets were
generated in the Auto Droplet Generator (BioRad)
followed by sealing of the plate and thermal cycling
under following conditions: 95 °C for 10 mins, 40 cycles
(94 °C for 30 s, 57.5 °C for 1 min), 98 °C for 10 mins, 12 °
C hold. The droplets were analyzed by a QX200 Droplet
Reader and QuantaSoft Software (BioRad), from which a
concentration (copies/μL) of methylated and unmethy-
lated cfDNA was obtained.
Statistics
Statistical analyses were executed in IBM Statistical
Packages for Social Sciences (SPSS, version 25) and
GraphPad Prism (Version 7.04, GraphPad Inc., La Jolla,
CA, U.S.A.) All clinical data are presented as means
(standard deviation (SD)) or medians (interquartile range
(IQR)). All data were tested with Shapiro-Wilks test for
normal distribution. For statistical analysis, non-normal
distributed data were log transformed and compared
with students t-test for paired or non-related samples.
INScfDNA was not normal distributed after log trans-
formation. Therefore, INScfDNA is presented as copies/
μL and unmethylated/methylated ratio. The differences
between groups were assessed using Kruskal-Wallis test
and Wilcoxon Signed rank test for repeated samples.
Correlations were assessed with Spearman’s correlation
for nonparametric data. A P-value of less than 0.05 was
considered signficant.
Results
Demographics of the study population
Basic anthropometric and biochemical characteristics
are shown in Table 1. Mean follow-up time was 5.8 years
(SD 0.8) (median: 6.1(min 4.0, max 7.1)). Of the 48
women, 33 PCOS (82.5%) and 6 controls (75.0%) gave
birth to at least one child between the BL examination
and FU. One control (2.6%) and one PCOS (2.6%) were
diagnosed with gestational diabetes and two (5.1%) (both
PCOS) with preeclampsia during pregnancy.
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There were no significant differences in weight, BMI,
waist-hip ratio, systolic and diastolic blood pressure be-
tween the 2 groups, neither at BL nor at FU. Comparing
BL and FU, both groups had increased their BMI and
waist measurement, whereas only the controls had sig-
nificantly increased weight and waist-hip-ratio at
follow-up. The PCOS group had significantly increased
their hip-measurements, but decreased their diastolic
blood pressure.
As expected, the PCOS group had increased levels of
androgens (Total Testosterone (T), Free T and Andro-
stenedione) and the ratio between luteinizing hormone
and follicle-stimulating hormone (LH/FSH ratio) at BL
and at FU compared with controls, although Free T
levels were not significantly different between PCOS and
controls at FU. Both groups significantly decreased their
levels of Total T and androstenedione during the FU
time. The PCOS group had further decreased their levels
of Free T, Dihydroepiandrosterone-sulfate (DHEAS) and
sex hormone binding globulin (SHBG).
At baseline two controls (4.3%) and three PCOS (6.4%)
were prediabetic (defined by IGT or IFG). At follow-up, one
control (2.2%) and seven PCOS (14.6%) were prediabetic.
None of the participants was diagnosed withT2D at baseline
or at follow-up. There were no significant differences in fast-
ing glucose, fasting insulin, fasting c-peptide, homeostatic
model assessment of insulin resistance (HOMA-IR) between
the controls and PCOS at BL or at FU. However, only the
PCOS group displayed significant increases in insulin,
c-peptide, HOMA-IR and triglycerides between BL and FU.
Table 1 Characteristics of the participants
Baseline Follow-up Baseline vs.
Follow-up
Control
n = 8
PCOS
n = 40
p Control
n = 8
PCOS
n = 40
p Controls
p
PCOS
p
Age (years) 30.0 (5.2) 29.1 (4.1) NS 35.6 (6.0) 34.7 (4.2) NS – –
Weight (kg) 72.3 (12.4) 77.6 (20.1) NS 79.2 (12.8) 78.5 (17.8) NS 0.03 NS
Height (cm) 169.8 (3.8) 168.5 (7.1) NS 171.3 (4.3) 168.5 (6.9) NS NS NS
BMI (kg/m2) 24.83 (4.2) 26.7 (5.2) NS 27.0 (4.3) 27.7 (6.1) NS 0.03 0.013
Waist (cm) 83.4 (8.5) 89.5 (12.8) NS 90.8 (11.0) 91.7 (15.0) NS 0.02 0.018
Hip (cm) 106.6 (7.8) 107.8 (9.1) NS 108.0 (8.0) 109.2 (11.5) NS NS 0.018
Waist-Hip Ratio 0.8 (0.1) 0.8 (0.1) NS 0.8 (0.6) 0.8 (0.1) NS 0.06 NS
Systolic Blood Pressure
(mmHg)
123.2 (17.2) 122.5 (11.0) NS 113.6 (18.1) 121.0 (12.9) NS NS NS
Diastolic Blood Pressure
(mmHg)
76.6 (13.5) 77.0 (10.8) NS 71.5 (17.1) 72.8 (11.2) NS NS 0.04
Ferriman Gallwey Score 2.5 (1.5–4.5) 5.0 (3.0–10.0) 0.019 1.5 (0–5.5) 6.0 (3.0–9.0) NS NS NS
Total testosterone (nmol/L) 0.9 (0.7–1.6) 1.9 (1.4–2.5) 0.001 0.7 (0.4–0.9) 1.4 (1.0–2.0) 0.02 0.039 < 0.001
Free testosterone (nmol/L) 0.019 (0.012–0.023) 0.032 (0.019–0.050) 0.016 0.012 (0.007–0.014) 0.023 (0.014–0.036) NS NS 0.008
DHEAS (Umol/L) 5181 (1962) 5676 (2764) NS 4437 (2550) 4857 (2190) NS NS 0.017
Androstenedione (nmol/L) 4.4 (3.0–5.7) 7.1 (4.7–9.0) 0.008 2.8 (1.8–3.4) 5.8 (4.0–8.5) < 0.001 0.001 0.048
SHBG (nmol/L) 62.5 (45.0–73.5) 59.5 (40.0–83.0) NS 49.0 (30.0–72.5) 46.0 (36.5–83.0) NS NS 0.011
LH/FSH ratio 0.7 (0.5–1.2) 1.7 (1.2–2.3) < 0.001 0.8 (0.8–1.1) 1.6 (1.1–2.2) 0.02 NS NS
Fasting s-glucose (mmol/L) 5.3 (0.8) 5.1 (0.4) NS 4.8 (0.7) 4.9 (0.5) NS NS 0.029
s-insulin (pmol/L) 58.8 (40.8–84.1) 45.7 (33.0–104.1) NS 56.7 (38.6–110.9) 60.1 (37.7–108.9) NS NS 0.014
s-C-peptide (nmol/L) 0.6 (0.6–0.7) 0.6 (0.4–0.8) NS 0.7 (0.6–0.7) 0.7 (0.5–1.0) NS NS < 0.001
HOMA IR
(mU*mmol/L2)
13.9 (10.1–18.9) 10.3 (7.4–22.7) NS 11.0 (8.2–27.8) 12.9 (7.6–24.8) NS NS 0.056
Total cholesterol (mmol/L) 4.7 (0.7) 4.6 (0.8) NS 4.3 (0.8) 4.5 (0.8) NS NS NS
LDL cholesterol (mmol/L) 2.9 (0.7) 2.6 (0.7) NS 2.5 (0.7) 2.6 (0.8) NS NS NS
HDL cholesterol (mmol/L) 1.4 (0.2) 1.60 (0.5) NS 1.4 (0.3) 1.6 (1.2) NS NS NS
Triglyceride (mmol/L) 0.70 (0.7–0.8) 0.7 (0.6–1.2) NS 0.9 (0.9–1.2) 0.8 (0.7–1.6) NS NS 0.001
Legend: Baseline characteristics of the study participants. Data are presented as mean ± SD or as medians (interquartile range) if not normally distributed. Values
were considered significantly different at P < 0.05. Abbreviations: HOMA-IR homeostatic model assessment of insulin resistance, HDL high-density lipoprotein, LDL
low-density lipoprotein, LH Luteinizing Hormone, FSH Follicle Stimulating Hormone, DHEAS Dehydroepiandrosterone, SHBG Sex Hormone-Binding Globulin, NS
not significant
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Digital droplet PCR analysis of methylated and
unmethylated insulin promotor cfDNA in serum
The number of serum samples without detectable levels
of unmethylated INScfDNA was 23 (47.9% (17 PCOS
(42.5% of PCOS) and 6 controls (75.0% of controls)))
and 21 (43.8% (17 PCOS (42.5% of PCOS) and 4 con-
trols (50% of controls))) at BL and FU, respectively. Nine
(18.8% (6 PCOS (15.0% of PCOS) and 3 controls (37.5%
of controls)) and seven (14.6% (6 PCOS (15.5% of PCOS)
and 1 control (12.5% of controls)) samples from each
visit, respectively, had no or undetectable levels of meth-
ylated INScfDNA.
When comparing controls and PCOS for counts of
unmethylated INScfDNA (copies/μL), there was no sig-
nificant difference at baseline (p = 0.27) or at follow-up
(p = 0.99) (Fig. 1a). Similarly, when we compared the
counts of methylated insulin promotor cfDNA, there
was no significant difference between the PCOS and
control groups at baseline (p = 0.94) and follow up (p =
0.50) (Fig. 1b).
Because there was no difference in levels of INScfDNA
between PCOS and controls, we pooled the data from
each group at BL and at FU to increase power. However,
after pooling these data, there was no difference in
unmethylated or methylated INScfDNA, when compar-
ing baseline and follow-up values (p = 0.43 and p = 0.38)
(Fig. 1c). Further, there were no differences in total
amount of total INScfDNA (unmethylated + methylated
INScfDNA) between the groups neither at baseline nor
at follow-up (BL: p = 0.74 and FU: p = 0.79) (Fig. 2a).
The total amount of INScfDNA showed no differences
for all participants between baseline and follow-up (p =
0.25) (Fig. 2b).
Figure 3 shows the ratio between unmethylated and
methylated insulin cfDNA. When comparing ratios for
the PCOS versus the control group at BL and FU, there
were no significant differences (p = 0.18 and p = 0.48).
Likewise, no differences were detected during the 6 yr.
FU for each group (controls p = 0.13 and PCOS p =
0.52).
Subanalysis of unmethylated and methylated insulin
cfDNA in prediabetic and glucose tolerant participants
Since the number of baseline (n = 2) and follow-up (n =
1) controls with prediabetes (defined by IFG or IGT)
were very low, it was not possible to conduct analysis on
prediabetic versus glucose-tolerant participants individu-
ally in the groups of PCOS and controls. Comparing
methylated INScfDNA for all prediabetic participants
(both controls and PCOS) with all glucose tolerant par-
ticipants, no difference were seen neither at baseline
(p = 0.72) nor at follow-up (p = 0.07) (Additional file 2).
A similar nonsignificant result were seen for unmethy-
lated INScfDNA values at baseline and at follow-up (p =
0.27 and p = 0.11) (Additional file 2)). To analyze the
predictive capability of methylated or unmethylated
INScfDNA, we compared the baseline levels of
INScfDNA for the participants who were diagnosed with
prediabetes at FU with those who were glucose tolerant
at follow-up. This analysis showed no significant differ-
ences in unmethylated INScfDNA (p = 0.53) or methyl-
ated INScfDNA (p = 0.07). A binary logistic regression
model including BMI revealed no further significant pre-
dictive utility of unmethylated INScfDNA (p = 0.74) or
methylated INScfDNA (p = 0.65).
Association of unmethylated and methylated insulin
cfDNA and clinical markers of metabolic syndrome or
PCOS
No strong statistically significant correlations were iden-
tified between unmethylated or methylated insulin
cfDNA and weight, BMI, waist-hip ratio, blood pressure,
lipids (total cholesterol, HDL- or LDL-cholesterol and
triglyceride), insulin, c-peptide, glucose, HOMA-IR or
androgen status (FG-score, free testosterone, total
testosterone, androstenedione, SHBG and DHEAS)
(Additional file 3)), neither at baseline nor at follow-up.
Discussion
Islet β-cell death is known to be a common denominator
in progression to type 1 or type 2 diabetes. Β-cell death
in T2D is well known to be associated with exogenous
insulin requirement. However, there are several lines of
evidence [25] indicating that progression to Type 2 dia-
betes itself may result following loss of functional islet
β-cells. Thus, our study aimed to measure biomarkers of
islet β-cell death (i.e INS cfDNA) in PCOS/Control
women who would develop T2D in future. At the mo-
ment, there is a consensus that elevated levels of
unmethylated INScfDNA correlate with β-cell death and
T1D in mice and humans [8, 10, 12], whereas methyl-
ated cfDNA is suggested as a marker of inflammation or
sepsis [11]. With this study, we investigated whether this
relatively new method could be used for detecting early
signs of β-cell death and T2D in women with PCOS.
Our results could not confirm this hypothesis, as we did
not find any differences in methylated or unmethylated
INScfDNA when we compared PCOS women with
healthy controls. Likewise, we could not detect any in-
crease in methylated or unmethylated INScfDNA over a
period, even though the PCOS group presented with a
more metabolically challenged profile at FU. Neither did
we find a correlation between markers of insulin resist-
ance and metabolic syndrome and insulin promotor
DNA methylation status.
There are several issues that could contribute to these
negative findings. First: the insulin gene and its promo-
tor contain several methylation sites, but not all of them
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display a unique methylation pattern in β-cells compared
with other tissues [26]. The tissue specificity of these
methylation sites is essential for their usefulness as bio-
markers of β-cell death. The evidence though is still
sparse on this and there is no consensus of which sites
that are the best determinants of islet β-cell stress or
death and of future progression to T1D. Previous studies
have also used the CpG site (− 69) upstream the TSS of
the insulin gene, and reported increased levels of both
unmethylated and methylated insulin cfDNA in patients
with T1D, but not in patients with T2D [6]. Another
study [27] primarily tested downstream CpG sites (lo-
cated at + 255, + 273, + 303, + 329, + 364, + 370, + 396
and + 399) within the coding region of the insulin gene
and confirmed increased levels of unmethylated cfDNA
in patients with T1D as well as subjects with increased
risk of T1D [28]. A third group identified a cluster of six
other CpG sites, within the insulin promoter, with Illu-
mina 450 K methylation arrays and next-generation se-
quencing, that was able to distinguish between healthy
controls and patients with T1D [29].
Secondly, little research into INScfDNA has been done
in patients with T2D, and none on women with PCOS.
Likewise, the existing studies report results with some
discrepancy. Studies indicate that the DNA methylation
is not stable and not all CpG sites are consistently meth-
ylated during periods of cellular stress, which could be
an explanation to the inconsistency in findings [7]. Fur-
ther, it is most likely that the DNA methylation during
T2D occurs at multiple loci with small effect sizes that
contribute to an increased risk for disease [30]. Hetero-
geneity in the methylation sites affected would decrease
the sensitivity of a cfDNA biomarker.
Fisher et al. [6] used the CpG site (− 69) and found
that neither methylated nor unmethylated cfDNA levels
were increased in patients with T2D compared with con-
trols. Another group investigated the DNA methylation
in 25 CpG sites within the insulin promoter and gene in
pancreatic islets from patients with T2D and controls
[7]. They reported that four sites (located at − 234, −
180, − 102 and + 63) showed increased methylation in
pancreatic β-cells from patients with T2D compared
with controls. Furthermore, they showed that the per-
centage of DNA-methylation was positively correlated to
HbA1C, but negatively correlated with insulin mRNA ex-
pression. [7] These findings indicate that increased DNA
A
B
C
Fig. 1 Panel a: Methylated INScfDNA. Panel b: Unmethylated
INScfDNA. Panel c: Baseline vs. Follow-up. Number of copies/mL of
respectively unmethylated (a) and methylated (b) INScfDNA. PCOS
and control group compared at baseline (BL) and follow-up (FU). BL
and FU for all samples expressed by copies/uL, are compared in
panel c. Results are expressed as medians (95%CI). NS:
Not significant
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methylation of the insulin promotor in the pancreas
could be a contributor to the downregulation of insulin
expression in T2D as a pathological response to hyper-
glycemia. This is in line with the findings of Kenna et al.
[31] who investigated the methylation pattern in women
with gestational diabetes compared with pregnant
women without gestational diabetes. They suggested that
a decreased fraction of unmethylated insulin promotor
DNA is a reflection of a decreased β-cell turnover and
the decreased turnover could be a mechanism to com-
pensate for the need for higher insulin levels.
Third, PCOS is a heterogeneous condition – there is
variation within the group mainly explained by the syn-
drome definition of PCOS [1, 32], but also variation over
time caused by e.g. pregnancy or interventions in life-
style [33–35]. Some studies show that the different
PCOS phenotypes differs in cardiometabolic risk, with
the highest risk in hyperandrogenic and anovulatory
phenotypes [4, 5]. However, we did not detect any differ-
ences in unmethylated or methylated INScfDNA neither
at baseline nor at follow-up in a subanalysis of PCOS
phenotypes based on Rotterdam criteria (data not
shown). Further, the cohort was recruited when referred
to assisted reproductive treatment (ART), and as a
standard procedure, all PCOS women with a BMI > 25
are asked to initiate lifestyle interventions. Looking at
weight only, the control group increased theirs during
FU, while the PCOS group did not. The steady weight in
the PCOS group could be interpreted as an alteration in
general lifestyle. The fact that our cohort is recruited
prior to ART, could also have caused selection bias, as
those women with need of ART possibly are challenged
with a severe PCOS phenotype. Moreover, our partici-
pants were relatively young at the follow-up time point
in terms of developing insulin resistance, prediabetes or
T2D. The effect on INScfDNA methylation pattern
could have been more pronounced if the participants
were older or if the follow-up time had been longer. An-
other explanation to the negative results is a possible ef-
fect of PCOS status on liver function or the use of
metformin in the PCOS women. PCOS women are
known to have an increased risk of developing
non-alcoholic fatty liver disease (NAFLD) [36], and al-
though there is no studies on NAFLD and INScfCNA
counts, one study have indicated that the presence of
autoimmune hepatitis has a decreasing effect on levels
of methylated and unmethylated INScfDNA compared
with controls [6]. This could cause an underestimation
of the differences between the groups and thereby our
results. The use of metformin could also be a con-
founder in our study. There are no studies of the effect
A B
Fig. 2 Panel a: Total INScfDNA. Panel b: Total INScfDNA. Total amount of INScfDNA (umethylated + methylated copies/uL). PCOS and controls are
compared in panel a and BL vs FU in panel b. Results are expressed as medians (95%CI). NS: Not significant
Fig. 3 Ratio Unmethylated/methylated INS cfDNA. Ratio between
unmethylated and methylated INS cfDNA (copies/μL/copies/μL).
Results are expressed as medians (95%CI)
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of metformin on INScfDNA counts, but insulin treat-
ment in newly diagnosed T1D is shown to reduce both
methylated and unmethylated INScfDNA significantly
[6]. If the effect of metformin is similar, use of metfor-
min in the PCOS group could also cause an underesti-
mation of the differences between the groups.
Unfortunately, we have no reliable records of the met-
formin use in our cohort between baseline and
follow-up. Finally, one could argue that our sample size,
and especially the control group, is too small. This study
was designed with an assumption of that, in a PCOS co-
hort aged 30–40 and BMI > 25, the prevalence of predia-
betes (IGT or IFG) would be approximately 40–45% [37]
at follow up. The prevalence in our cohort did not fulfill
this assumption, as only 17.5% of our PCOS cohort was
prediabetic, causing very low power. If the prevalence
had been as expected, the power would had been accept-
able. The lower number of participating controls re-
sulted due to a recruitment issue, which might cause an
underestimation of the differences between PCOS and
controls.
We were not able to detect any differences in
unmethylated or methylated INScfDNA at any time in
this study. However looking at samples with undetect-
able levels INScfDNA, there are a relatively larger num-
ber of samples without detectable levels of unmethylated
INScfDNA, than of methylated INScfDNA. This advo-
cates the theory of PCOS as an inflammatory condition
with increased cell-turnover in general, as suggested by
others [38, 39], even though we did not detect significant
differences between controls and PCOS.
Conclusion
The cell-free DNA methylation pattern of the insulin
gene promoter has been suggested as a marker of
pancreatic islet β-cell destruction, and thereby as an
early marker of diabetes. Since islet β-cell death is a
common denominator in T1D as well as T2D, we ex-
plored if circulating insulin cell-free DNA can deter-
mine differences in BL and 6 year follow-up samples
in a cohort of women with PCOS or without. We
were not able to detect any differences in the levels
of INScfDNA between PCOS and controls at BL as
well as over a period of 6 years. Although these nega-
tive findings could be a result of the heterogeneous
nature of PCOS or by the relatively short follow-up
time, the publication of negative findings is an im-
portant contribution to scientific understanding of a
topic, avoiding publication bias by preferentially pub-
lishing only papers with positive results increasing the
risk that an incorrect prevailing view can persist. Fur-
ther studies in larger and longer longitudinal cohorts
are warranted.
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